Heerma Peter sold $17.9M of TVTX
Heerma Peter (EVP, CHIEF COMMERCIAL OFFICER) sold 283,189 shares of Travere Therapeutics, Inc. (TVTX) at an average of $63.06 ($62.05–$65.31, $17.86M total) across 7 trades over 2026-09-15 to 2026-09-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership by ~70%, which could be interpreted as reduced confidence but may simply reflect a liquidity event.
Market read
Insider sell of this magnitude is noteworthy for traders monitoring biotech stocks; could influence short‑term price action.
What to watch
Potential upcoming clinical data releases or partnership announcements could offset sell‑off concerns.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.
Ticker impact
EVP and Chief Commercial Officer sold 283,189 shares for $17.9M via a 10b5‑1 plan, reducing his stake to 117,066 shares.
Short‑term downward pressure; watch for further insider activity.
The sale size (~$18M) is material for a mid‑cap biotech; executed under a pre‑arranged plan, but still reduces insider ownership.
Market effects
May raise questions about commercial outlook for Travere Therapeutics within the rare‑disease biotech sector.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The 10b5‑1 plan suggests the sale was pre‑scheduled, not a reaction to new information; the stock may remain stable.
Key entities
- OfficerHeerma Peter
EVP, Chief Commercial Officer of Travere Therapeutics.
- CompanyTravere Therapeutics, Inc.
Biopharmaceutical company focused on rare diseases.
